WO2004073587A3 - Diagnostics et traitements de maladies associees au recepteur de la parathormone 1 (pthr1) - Google Patents
Diagnostics et traitements de maladies associees au recepteur de la parathormone 1 (pthr1) Download PDFInfo
- Publication number
- WO2004073587A3 WO2004073587A3 PCT/EP2004/001099 EP2004001099W WO2004073587A3 WO 2004073587 A3 WO2004073587 A3 WO 2004073587A3 EP 2004001099 W EP2004001099 W EP 2004001099W WO 2004073587 A3 WO2004073587 A3 WO 2004073587A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diseases
- disorders
- pthr1
- therapeutics
- diagnostics
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 102000006461 Parathyroid Hormone Receptors Human genes 0.000 title 1
- 108010058828 Parathyroid Hormone Receptors Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 208000012239 Developmental disease Diseases 0.000 abstract 2
- 101000589873 Homo sapiens Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000012931 Urologic disease Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 208000037765 diseases and disorders Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000002124 endocrine Effects 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 2
- 230000002093 peripheral effect Effects 0.000 abstract 2
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 2
- 208000014001 urinary system disease Diseases 0.000 abstract 2
- 102100032256 Parathyroid hormone/parathyroid hormone-related peptide receptor Human genes 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000051132 human PTH1R Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne un PTHR1 humain qui est associé aux maladies cardio-vasculaires, aux troubles du système nerveux périphérique et central, à l'inflammation, aux maladies urologiques, aux troubles du développement, au cancer, aux maladies métaboliques, aux maladies endocrinologiques et aux troubles du système gastro-intestinal. L'invention concerne également des dosages permettant d'identifier des composés utiles dans le traitement ou la prévention des maladies cardio-vasculaires, des troubles du système nerveux périphérique et central, de l'inflammation, des maladies urologiques, des troubles du développement, du cancer, des maladies métaboliques, des maladies endocrinologiques et des troubles du système gastro-intestinal. L'invention concerne également des composés qui se lient à PTHR1 et/ou activent ou inhibent l'activité de PTHR1 ainsi que des compositions pharmaceutiques comprenant ces composés.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03003174.4 | 2003-02-19 | ||
EP03003174 | 2003-02-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004073587A2 WO2004073587A2 (fr) | 2004-09-02 |
WO2004073587A3 true WO2004073587A3 (fr) | 2005-01-06 |
Family
ID=32892845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/001099 WO2004073587A2 (fr) | 2003-02-19 | 2004-02-06 | Diagnostics et traitements de maladies associees au recepteur de la parathormone 1 (pthr1) |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2004073587A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10519250B2 (en) | 2016-08-01 | 2019-12-31 | Xoma (Us) Llc | Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof |
CA3217862A1 (fr) | 2021-05-05 | 2022-11-10 | Radius Pharmaceuticals, Inc. | Modele animal ayant une recombinaison homologue du recepteur pth1 de souris |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998051324A1 (fr) * | 1997-05-14 | 1998-11-19 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Analogues peptidiques de l'hormone parathyroide |
US5840853A (en) * | 1991-04-05 | 1998-11-24 | The General Hospital Corporation | Parathyroid hormone receptor and DNA encoding same |
WO2001009328A1 (fr) * | 1999-08-03 | 2001-02-08 | Millennium Pharmaceuticals, Inc. | Nouvelle molecule 15571 de type gpcr de la famille secretine et utilisations de cette derniere |
WO2001077172A2 (fr) * | 2000-04-07 | 2001-10-18 | Arena Pharmaceuticals, Inc. | Recepteurs connus couples a la proteine g non endogenes a activation constitutive |
WO2002061087A2 (fr) * | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques |
-
2004
- 2004-02-06 WO PCT/EP2004/001099 patent/WO2004073587A2/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840853A (en) * | 1991-04-05 | 1998-11-24 | The General Hospital Corporation | Parathyroid hormone receptor and DNA encoding same |
WO1998051324A1 (fr) * | 1997-05-14 | 1998-11-19 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Analogues peptidiques de l'hormone parathyroide |
WO2001009328A1 (fr) * | 1999-08-03 | 2001-02-08 | Millennium Pharmaceuticals, Inc. | Nouvelle molecule 15571 de type gpcr de la famille secretine et utilisations de cette derniere |
WO2001077172A2 (fr) * | 2000-04-07 | 2001-10-18 | Arena Pharmaceuticals, Inc. | Recepteurs connus couples a la proteine g non endogenes a activation constitutive |
WO2002061087A2 (fr) * | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques |
Non-Patent Citations (1)
Title |
---|
QIAN J ET AL: "REDUCED BLOOD PRESSURE AND INCREASED SENSITIVITY OF THE VASCULATURE TO PARATHYROID HORMONE-RELATED PROTEIN (PTHRP) IN TRANSGENIC MICE OVEREXPRESSING THE PTH/PTHRP RECEPTOR IN VASCULAR SMOOTH MUSCLE", ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 140, no. 4, April 1999 (1999-04-01), pages 1826 - 1833, XP001193328, ISSN: 0013-7227 * |
Also Published As
Publication number | Publication date |
---|---|
WO2004073587A2 (fr) | 2004-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005093092A3 (fr) | Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44) | |
WO2004097421A3 (fr) | Diagnostics et traitements destines a des maladies associees au recepteur de type recepteur calcitonine (calcrl) | |
WO2004073587A3 (fr) | Diagnostics et traitements de maladies associees au recepteur de la parathormone 1 (pthr1) | |
WO2004099782A3 (fr) | Approche diagnostique et therapeutique des maladies associees au recepteur gpr39 (gpr39) couple a une proteine g | |
WO2004042402A3 (fr) | Moyens diagnostiques et therapeutiques destines a des maladies associees au mrgx1 humain | |
WO2004038405A3 (fr) | Diagnostics et therapeutiques pour maladies liees au recepteur 43 couple a la proteine g (gpr43) | |
WO2004099783A3 (fr) | Diagnostics et therapies destines a des maladies associees au recepteur ltb4 (ltb4) couple a la proteine g | |
WO2004071378A3 (fr) | Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies au recepteur hm74a couple a la proteine g | |
WO2004082570A3 (fr) | Diagnostics et traitements contre des maladies associees au recepteur d2 de la dopamine (drd2) | |
WO2004106935A3 (fr) | Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 103 couples aux proteines g (gpr103) | |
WO2004081563A3 (fr) | Moyens de diagnostic et therapeutiques pour des maladies associees a la phosphodiesterase 1a (pde1a) | |
WO2004038421A3 (fr) | Agents diagnostiques et therapeutiques pour maladies associees au recepteur 41 couple a une proteine g humaine (gpr41) | |
WO2004071396A3 (fr) | Diagnostics et therapeutique pour des maladies associees au recepteur 2 de l'hormone parathyroide (pthr2) | |
WO2004048978A3 (fr) | Procedes pour diagnostiquer et traiter des maladies associees au recepteur 37 couple a la proteine g d'acide biliaire (bg37) | |
WO2004099248A3 (fr) | Produits de diagnostic et de traitement de maladies associees au recepteur agtr2 couple aux proteines g (agtr2) | |
WO2004071393A3 (fr) | Diagnostic et therapeutique pour des maladies associees au recepteur peptide 1 de type glucagon | |
WO2003066077A3 (fr) | Outil de diagnostic et therapeutique pour des maladies associees au recepteur de neuromedine u1 (nmu1) | |
WO2004042077A3 (fr) | Diagnostics et traitements de maladies associees a la phosphodiesterase 8b humaine (pde8b) | |
WO2005101001A3 (fr) | Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees au recepteur couple a la proteine g, element c, groupe 5, famille c (gprc5c) | |
WO2004086047A3 (fr) | Agents diagnostiques et therapeutiques de maladies associees a adenosine a1 du recepteur couple a la proteine g (adora1) | |
WO2004099781A3 (fr) | Approches diagnostique et therapeutique des maladies associees au recepteur rdc1 (rdc1) couple a une proteine g | |
WO2005093091A3 (fr) | Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26) | |
WO2003076945A3 (fr) | Diagnostic et therapie de maladies associees au recepteur couple a la proteine g 105 (gpr105) | |
WO2005040790A3 (fr) | Diagnostics et therapeutiques pour maladies liees au recepteur 75 couple a la proteine g (gpr75) | |
WO2005108998A3 (fr) | Methodes de diagnostic et de traitement de maladies associees au recepteur couple aux proteines g adrenergique beta-3 (adrb3) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |